Common Diabetes Drug Linked to 'Exceptional Longevity' in Women
Not only can the drug metformin help to effectively manage type 2 diabetes, it may also give older women a better chance of living to the grand old age of 90, according to new research – thanks, it seems, to a variety of anti-aging effects.
The research used data from a long-term US study of postmenopausal women. Records on a total of 438 women were picked out – half who took metformin for their diabetes, and half who took a different diabetes drug, called sulfonylurea.
While there are a lot of caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group.
"Metformin has been shown to target multiple pathways of aging and therefore has been postulated as a drug that may extend human longevity," write the researchers in their published paper.
"We found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes."
We already know quite a lot about metformin. It's been around for decades, and is considered a gerotherapeutic: a drug able to slow down various aging processes in the body. For example, it's been shown to limit DNA damage and promote gene activity associated with long life.
Previous studies have shown metformin can put the brakes on wear and tear in the brain, and even reduce the risk of long COVID. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study.
This research can't prove cause and effect like a randomized control trial (RCT) might be able to, because the participants weren't randomly assigned to one treatment or the other – rather, they were following professional advice. What's more, there was no placebo group given no treatment at all. The overall sample size wasn't particularly large, either.
However, the study also has its strengths – not least the average 14 to 15 years of follow-up, which goes way beyond the length a standard RCT would be able to. That's important when you're trying to see how lifespan is affected.
"A key advantage of our analysis was the long follow-up period after treatment initiation enabled by examination of a cohort with extensive follow-up from midlife to ages 90 and older, which is not feasible in typical randomized controlled trials," write the researchers.
RCTs could be something that follows further down the line to dig deeper into these results, the researchers suggest. In the meantime, with the global population continuing to skew older and older, studies continue to find ways of keeping us healthier for longer, and reducing damage to the body as we age.
"The geroscience hypothesis posits that biological aging is malleable and that slowing biological aging may delay or prevent the onset of multiple age-related diseases and disability," write the researchers.
"A key goal of geroscience is to identify novel therapeutic and preventive interventions that slow biological aging."
The research has been published in the Journal of Gerontology: Medical Sciences.
Increased Toxicity Risk Identified For Children With ADHD, Autism
Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover
Texas Woman Dies From Brain-Eating Amoeba After Flushing Sinuses
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Common Diabetes Drug Linked to 'Exceptional Longevity' in Women
Not only can the drug metformin help to effectively manage type 2 diabetes, it may also give older women a better chance of living to the grand old age of 90, according to new research – thanks, it seems, to a variety of anti-aging effects. The research used data from a long-term US study of postmenopausal women. Records on a total of 438 women were picked out – half who took metformin for their diabetes, and half who took a different diabetes drug, called sulfonylurea. While there are a lot of caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. "Metformin has been shown to target multiple pathways of aging and therefore has been postulated as a drug that may extend human longevity," write the researchers in their published paper. "We found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes." We already know quite a lot about metformin. It's been around for decades, and is considered a gerotherapeutic: a drug able to slow down various aging processes in the body. For example, it's been shown to limit DNA damage and promote gene activity associated with long life. Previous studies have shown metformin can put the brakes on wear and tear in the brain, and even reduce the risk of long COVID. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. This research can't prove cause and effect like a randomized control trial (RCT) might be able to, because the participants weren't randomly assigned to one treatment or the other – rather, they were following professional advice. What's more, there was no placebo group given no treatment at all. The overall sample size wasn't particularly large, either. However, the study also has its strengths – not least the average 14 to 15 years of follow-up, which goes way beyond the length a standard RCT would be able to. That's important when you're trying to see how lifespan is affected. "A key advantage of our analysis was the long follow-up period after treatment initiation enabled by examination of a cohort with extensive follow-up from midlife to ages 90 and older, which is not feasible in typical randomized controlled trials," write the researchers. RCTs could be something that follows further down the line to dig deeper into these results, the researchers suggest. In the meantime, with the global population continuing to skew older and older, studies continue to find ways of keeping us healthier for longer, and reducing damage to the body as we age. "The geroscience hypothesis posits that biological aging is malleable and that slowing biological aging may delay or prevent the onset of multiple age-related diseases and disability," write the researchers. "A key goal of geroscience is to identify novel therapeutic and preventive interventions that slow biological aging." The research has been published in the Journal of Gerontology: Medical Sciences. Increased Toxicity Risk Identified For Children With ADHD, Autism Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover Texas Woman Dies From Brain-Eating Amoeba After Flushing Sinuses
Hindustan Times
3 days ago
- Hindustan Times
Weight gain to acne: Doctor explains 6 common challenges faced by women due to PCOS; shares prevention tips
Polycystic Ovary Syndrome (PCOS) is a common hormonal disorder that affects a large number of women worldwide. It is often characterised by symptoms such as weight gain, irregular menstrual cycles, excessive facial hair, and mood swings. In an interview with HT Lifestyle, Dr. Manjusha Goel, lead consultant, dept of obstetrics and gynaecology at the CK Birla Hospital, Delhi spike about the common challenges that women face due to PCOS. One of the most common symptoms of PCOS is irregular menstrual cycles, which can make it difficult to predict periods and may lead to complications such as endometrial thickening. Hormonal imbalances can prevent ovulation, making it harder for women with PCOS to conceive. It's one of the leading causes of infertility among women. Also read | Acne to infertility: Hidden impact of PCOS on women's health Many women with PCOS struggle with weight gain, particularly around the abdomen. PCOS is also linked with insulin resistance, which can further contribute to weight issues and increase the risk of developing type 2 diabetes. Excess androgen levels in PCOS can lead to skin problems like acne and unwanted hair growth (hirsutism), which can affect self-esteem and confidence. The physical symptoms, along with issues like infertility and body image concerns, often lead to anxiety, depression, and low self-esteem. If left unmanaged, PCOS can increase the risk of serious conditions such as heart disease, high blood pressure, sleep apnea, and endometrial cancer. Weight management: Even a modest weight loss (5-10%) can significantly improve hormonal balance, restore menstrual regularity, and enhance fertility. Healthy diet: A diet rich in whole grains, fruits, vegetables, lean proteins, and healthy fats, while low in refined sugars and processed carbs, can help regulate insulin and support hormone balance. Regular exercise: Physical activity not only helps with weight management but also improves insulin sensitivity, mood, and overall well-being. Hormonal birth control: Oral contraceptives can regulate periods, reduce acne, and lower the risk of endometrial cancer. Metformin: Commonly used to improve insulin sensitivity and help with menstrual regularity. Androgen-blocking medications: These can help reduce symptoms like acne and excessive hair growth. Fertility treatments: For women trying to conceive, ovulation-inducing medications or assisted reproductive technologies may be recommended. Also read | Difference between PCOS and PCOD: Their symptoms, causes, treatment and prevention Laparoscopic surgery: In some cases, procedures like ovarian drilling can help stimulate ovulation. Regular health checkups: Monitoring blood sugar, cholesterol, and hormonal levels is essential. Support groups and counseling: Emotional support through peer groups or therapy can help cope with the psychological effects. Family and social support: Having a strong support system can make a significant difference in emotional well-being and long-term management. Educational programs: Awareness and education help women understand the condition better and encourage timely intervention. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
29-05-2025
- Yahoo
NY man alleges vision loss after taking Ozempic: Details
The Brief A 48-year-old man from Suffolk County blames Ozempic for partial vision loss in both eyes. He, along with over 30 others who are suffering from the same side effect, are suing Ozempic's manufacturer. The manufacturer, Novo Nordisk, states they believe "the benefit-risk profile of semaglutide remains unchanged." LONG ISLAND - Michael, a 48-year-old from Suffolk County, is suing Ozempic's manufacturer for partial loss of vision. What we know Michael, who opted out of sharing his surname, says that the loss of sight began after his endocrinologist recommended he switch from Metformin to Ozempic to manage his type 2 diabetes. Michael told FOX 5 NY's Jodi Goldberg that he lost 10 pounds, but also some vision in both eyes. "From the bottom right side of my eye… if I close the left eye, faces get blurry, I can't read my cell phone." He claims he had 20/20 vision before taking Ozempic. Michael was diagnosed with NAION (Non-arteritic Anterior Ischemic Optic Neuropathy), which is essentially a stroke of the eye – it presents as an acute but painless loss of vision in one eye. No treatment for NAION currently exists. One of the most recognized risk factors for NAION is diabetes. However, two recent studies – one from the JAMA Network and the other out of Denmark – suggest there could be a link between the condition and taking semaglutide, which is the active ingredient in Ozempic. Jason Goldstein of Parker Waichman LLP, a personal injury, mass tort and environmental law firm, has filed a multimillion dollar lawsuit against Novo Nordisk, the manufacturer of Ozempic and Wegovy, a similar medication. Goldstein is representing more than 30 clients from 10 states suffering from the same side effect, including Michael. "This lawsuit is about holding Novo Nordisk responsible for not warning doctors and their patients this condition could develop," Goldstein said. Dig deeper Over the past decade, the U.S. Food and Drug Administration (FDA) has recalled over 14,000 drugs; rare side effects can be missed during clinical trials and may not be discovered until later on. Goldberg spoke to Dr. Chetna Bakshi about how common reactions to medications like Ozempic could be. Bakshi's take is that more research is necessary. "These medications come out, people take them, and it's not until 10 or 15 years later that we find other complications that weren't apparent in the initial clinical trials." The other side A spokesperson for Novo Nordisk gave FOX 5 this statement: "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously. After a thorough evaluation of studies from the University of Southern Denmark and Novo Nordisk's internal safety assessment, Novo Nordisk is of the opinion that the benefit-risk profile of semaglutide remains unchanged." Goldstein's response: "It was a drug you were taking, that there were other options on the market, and no one warned you this could happen." The Source This article includes reporting from FOX 5 NY's Jodi Goldberg, as well as two medical studies from the JAMA Network and a Danish-Norwegian cohort.
